MIG-6 negatively regulates STAT3 phosphorylation in uterine epithelial cells

Area of Science:

• Reproductive biology
• Oncology
• Molecular endocrinology

Background:

• Endometrial cancer is the most common gynecologic malignancy.
• Progesterone (P4) therapy is used for fertility-sparing treatment, but P4 resistance is a clinical challenge.
• Understanding P4 resistance mechanisms is crucial for improving endometrial cancer treatment.

Purpose of the Study:

• To investigate the role of Mitogen-inducible gene 6 (Mig-6) in progesterone (P4) resistance in endometrial cancer.
• To elucidate the signaling pathways involved in P4 resistance and identify potential therapeutic targets.

Main Methods:

• Generated a mouse model with Mig-6 specifically ablated in uterine epithelial cells (Sprr2f^cre+Mig-6^f/f).
• Utilized immunoprecipitation and cell culture to study protein interactions and STAT3 phosphorylation.
• Administered P4 treatment to assess its effects on uterine epithelial cell proliferation and STAT3 phosphorylation.

Main Results:

• Mig-6 ablation in uterine epithelial cells led to endometrial hyperplasia via aberrant STAT3 phosphorylation.
• Mig-6 inhibited STAT3 phosphorylation through direct protein interactions.
• Despite Mig-6 ablation, Sprr2f^cre+Mig-6^f/f mice remained responsive to P4 treatment, which reduced STAT3 phosphorylation and proliferation.
• Antitumor effects of P4 were mediated by the endometrial stroma.

Conclusions:

• Mig-6 acts as a tumor suppressor in uterine epithelial cells by inhibiting STAT3 phosphorylation.
• The study reveals a novel signaling pathway for steroid hormone regulation in the uterus.
• Findings provide insights into overcoming P4 resistance in endometrial cancer and other reproductive diseases.